Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astria Therapeutics (ATXS) Equity Average: 2017-2019

Historic Equity Average for Astria Therapeutics (ATXS) over the last 3 years, with Sep 2019 value amounting to $40.8 million.

  • Astria Therapeutics' Equity Average fell 5.44% to $40.8 million in Q3 2019 from the same period last year, while for Sep 2019 it was $40.8 million, marking a year-over-year decrease of 5.44%. This contributed to the annual value of $23.4 million for FY2018, which is N/A change from last year.
  • According to the latest figures from Q3 2019, Astria Therapeutics' Equity Average is $40.8 million, which was down 12.44% from $46.6 million recorded in Q2 2019.
  • Over the past 5 years, Astria Therapeutics' Equity Average peaked at $46.6 million during Q2 2019, and registered a low of $12.4 million during Q1 2018.
  • Moreover, its 3-year median value for Equity Average was $33.6 million (2018), whereas its average is $30.8 million.
  • Examining YoY changes over the last 5 years, Astria Therapeutics' Equity Average showed a top increase of 243.04% in 2019 and a maximum decrease of 5.44% in 2019.
  • Astria Therapeutics' Equity Average (Quarterly) stood at $13.7 million in 2017, then skyrocketed by 174.91% to $37.7 million in 2018, then declined by 5.44% to $40.8 million in 2019.
  • Its Equity Average was $40.8 million in Q3 2019, compared to $46.6 million in Q2 2019 and $42.4 million in Q1 2019.